SPAS(SH:603168)2018-04-25 16:00Financial Performance - Revenue decreased by 15.52% to CNY 186,147,655.81 compared to the previous year[6] - Net profit attributable to shareholders decreased by 18.40% to CNY 40,852,483.69 year-on-year[6] - Basic earnings per share decreased by 20.00% to CNY 0.16 compared to the same period last year[6] - The weighted average return on equity decreased by 0.65 percentage points to 2.44%[6] - The company reported a net profit margin decline due to reduced revenue and higher costs[34] - The company's operating revenue for Q1 2018 was CNY 181,129,905.51, a decrease of 3.99% compared to CNY 187,890,079.43 in the same period last year[37] - Net profit for Q1 2018 was CNY 49,226,767.30, an increase of 11.88% compared to CNY 44,116,615.08 in Q1 2017[38] - The total profit for Q1 2018 was CNY 57,906,761.49, an increase from CNY 51,894,408.25 in Q1 2017[38] - The company incurred tax expenses of CNY 8,679,994.19 in Q1 2018, compared to CNY 7,777,793.17 in the previous year[38] Cash Flow and Liquidity - Operating cash flow increased significantly by 180.06% to CNY 89,934,958.46 compared to the same period last year[6] - Cash and cash equivalents decreased by 45.60% to CNY 238,479,657.47 due to investment in financial products[15] - Cash flow from purchasing goods and services decreased by 34.39% to ¥37,534,308.26, attributed to the company's self-production of a specific product[17] - The company reported a 99.25% decrease in cash received from investment activities, totaling ¥131,523,315.07, due to the redemption of financial products[17] - Cash payments for investment activities increased by 35% to ¥400,000,000, reflecting a rise in the purchase of financial products[17] - The company's cash and cash equivalents decreased to ¥238,479,657.47 from ¥438,414,623.27, indicating a significant reduction in liquidity[27] - The net cash flow from operating activities for the first quarter of 2018 was ¥89,934,958.46, a significant increase from ¥32,112,851.21 in the previous year, representing a growth of 179.5%[41] - Total cash inflow from operating activities amounted to ¥278,796,785.85, compared to ¥262,646,522.94 in the same period last year, indicating a year-over-year increase of 6.5%[41] - Cash outflow from operating activities decreased to ¥188,861,827.39 from ¥230,533,671.73, reflecting a reduction of 18.1%[41] - The ending cash and cash equivalents balance decreased to ¥238,479,657.47 from ¥497,521,701.60, a decline of 52.2%[42] Assets and Liabilities - Total assets increased by 0.49% to CNY 1,878,521,414.65 compared to the end of the previous year[6] - Net assets attributable to shareholders increased by 2.47% to CNY 1,698,135,507.15 year-on-year[6] - Total liabilities amounted to CNY 180,385,907.50, a decrease from CNY 212,125,324.42[29] - Total equity increased to CNY 1,731,996,115.82 from CNY 1,682,769,348.52, representing a growth of 2.9%[33] - Current assets totaled CNY 955,864,003.95, an increase from CNY 909,246,442.63 at the beginning of the year[32] - The total non-current assets were CNY 932,574,245.29, slightly down from CNY 938,704,501.46[32] Investment Activities - Investment income decreased by 45.16% to CNY 1,437,089.69 due to fewer maturing financial products this period[16] - The company has increased its investment limit for low-risk financial products to a total of ¥4 billion, allowing for more flexible fund management[19] - Cash inflow from investment activities was recorded at ¥131,523,315.07, down from ¥202,620,424.66, a decrease of 35.1%[41] - Cash outflow from investment activities increased significantly to ¥421,393,239.33 from ¥222,079,024.01, marking an increase of 89.9%[41] Operational Highlights - The company has completed the consistency evaluation of a specific eye drop product, with all quality indicators aligning with the original drug[22] - The company is actively pursuing the consistency evaluation work for its eye drop product in compliance with regulatory requirements[22] - The company plans to focus on expanding its market presence and developing new products in the upcoming quarters[34]